| Amount | Holding |
|---|---|
| 4.44% | Illumina, Inc |
| 4.40% | Repligen Corporation |
| 4.25% | |
| 4.06% | Lonza Group Ltd |
| 3.74% | Veeva Systems Inc |
| 3.72% | Vertex Pharmaceuticals Incorporated |
| 3.30% | CRISPR Therapeutics AG |
| 3.26% | Catalent, Inc |
| 3.16% | uniQure N.V |
| 2.85% | Agilent Technologies, Inc |
Expense Ratio Rating
0 /10
Expense Rating
5 /10
Market Score
6 /10
Category Score
0 /10
Market Size
6 /10
$HELX Alternatives
35%
FI Score
- helx
- ETF
- Other
Franklin Genomic Advancements ETF
Expenses: 0.50% (Better than 0% of similar funds)
This is a bad choice for a Other fund. See why ยป